REFERENCES
- Hensley ML, Hagerty KL, Kewalramani T, Green DM, Meropol NJ, et al.: American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol 27, 127– 145, 2009.
- Minton O, Strasser F, Radbruch L, and Stone P: Identification of factors associated with fatigue in advanced cancer: a subset analysis of the European Palliative Care Research Collaborative Computerized Symptom Assessment Data Set. J Pain Symptom Manage 43, 226– 235, 2012.
- Detmar SB, Aaronson NK, Wever LD, Muller M, and Schornagel JH: How are you feeling? Who wants to know? Patients’ and oncologists’ preferences for discussing health-related quality-of-life issues. J Clin Oncol 18, 3295– 3301, 2000.
- Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, et al.: Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition. Semin Hematol 34(3, Suppl 2), 4–12, 1997.
- Costantini M, Mencaglia E, Giulio PD, Cortesi E, Roila F, et al.: Cancer patients as “experts” in defining quality of life domains. A multicentre survey by the Italian Group for the Evaluation of Outcomes in Oncology (IGEO). Qual Life Res 9, 151–159, 2000.
- Braun DP, Gupta D, Grutsch JF, and Staren ED: Can changes in health related quality of life scores predict survival in stages III and IV colorectal cancer? Health Qual Life Outcomes 9, 62, 2011.
- Braun DP, Gupta D, and Staren ED: Predicting survival in prostate cancer: the role of quality of life assessment. Support Care Cancer 20, 1267– 1274, 2012.
- Braun DP, Gupta D, and Staren ED: Quality of life assessment as a predictor of survival in non-small cell lung cancer. BMC Cancer 11, 353, 2011.
- Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, et al.: American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol 30, 880–887, 2012.
- Chang WH, Liu JJ, Chen CH, Huang TS, and Lu FJ: Growth inhibition and induction of apoptosis in MCF-7 breast cancer cells by fermented soy milk. Nutr Cancer 43, 214–226, 2002.
- Kishida T, Beppu M, Nashiki K, Izumi T, and Ebihara K: Effect of dietary soy isoflavone aglycones on the urinary 16alpha-to-2-hydroxyestrone ratio in C3H/HeJ mice. Nutr Cancer 38, 209–214, 2000.
- Ohta T, Nakatsugi S, Watanabe K, Kawamori T, Ishikawa F, et al.: Inhibitory effects of bifidobacterium-fermented soy milk on 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced rat mammary carcinogenesis, with a partial contribution of its component isoflavones. Carcinogenesis 21, 937–941, 2000.
- Kung-Ming W: Method for inhibiting 15-lipoxygenase with fermented Glycine max (L.) extract (Patent No. 6685973). Alexandria, VA: U. S. Patent Office, 2004.
- Kung-Ming W: Method of using fermented glycine max (L) extract for enhancing natural killer cell activity (Patent No. 6733801). Alexandria, VA: U. S. Patent Office, 2004.
- Kung-Ming W: Methods for inhibiting cancer growth, reducing infection and promoting general health with a fermented soy extract (Patent No. 6855350). Alexandria, VA: Office U. S. Patent Office, 2005.
- Tsang YW, Chi KH, Hu CJ, Tseng CL, Tseng FW, et al.: Chemotherapy-induced immunosuppression is restored by a fermented soybean extract: a proof of concept clinical trial. Nutr Res 27, 679– 684, 2007.
- Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, et al.: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85, 365–376, 1993.
- Medical Dictionary for Regulatory Activities. Accessed from http://www.meddramsso.com/
- National Comprehensive Cancer Network: Cancer-Related Fatigue, Version 1. NCCN clinical practice guidelines in oncology. 2012.
- Zhang J, Huang SH, Li H, Li Y, Chen XL, et al.: Preoperative lymphocyte count is a favorable prognostic factor of disease-free survival in non-small-cell lung cancer. Med Oncol 30, 352, 2013.
- Chemotherapy drugs. Accessed from http://www.chemocare.com/bio/
- Innominato PF, Giacchetti S, Moreau T, Bjarnason GA, Smaaland R, et al.: Fatigue and weight loss predict survival on circadian chemotherapy for metastatic colorectal cancer. Cancer 119, 2564–2573, 2013.
- Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, and Morrow GR: Cancer-related fatigue: the scale of the problem. Oncologist 12(Suppl. 1), 4–10, 2007.